Randomized open label phase III trial of CEOP/IMVP. Dexa alternativing chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternativing chemotherapy for aggressive non-Hodgkin‘s lymphoma. - Fridrik,M.A.; Greil,R.; Hausmaninger,H.; Krieger,O.; Oppitz,P. (Annals of Hematology, 1997)